patritumab,ruxolitinib
amgen,daiichi sankyo,novartis,incyte
['patritumab', 'her3-dxd', 'bcsm', 'tnbc', 'rux,(-crux),(-trux)']
 presents part a of the phase 2 study looking at patritumab deruxtecan (her3-dxd) in patients with locally advanced or metastatic er+ or tnbc activity seen across a broad range of her3 expression with 35% orr. more studies ongoing. #bcsm #asco23 
Breast & gyn med onc @valleyhealthnj. Opinions my own. Host of INTERLUDE podcast 🎤 Co-lead @cosmocollab. Focus on survivorship and social media in oncology.